Exelixis Inc. Common Stock (EXEL) : juste valeur

Thèse ACCE

Exelixis sells Cabometyx (cabozantinib), an oral kinase inhibitor for advanced renal cell carcinoma and other solid tumors, and its growth rests on that franchise plus a steady royalty stream from Cometriq and partner-licensed programs. The moat is the patent and regulatory exclusivity around Cabometyx, which gives the company a 96.5% gross margin and a 39.5% operating margin on 10.6% revenue growth, a profile few mid-cap biotechs can match. The near-term swing factor is label expansion and pipeline readouts in the oncology portfolio, where any positive data or new indication would extend the revenue runway beyond current expectations. At a 14.6x forward P/E against a trailing 19.6x, the market is pricing in earnings growth without giving full credit for it, and a 44.4% ROE indicates the business converts capital efficiently. The main risks are concentration in one product and the eventual loss of exclusivity, so this name merits a deeper look focused on the patent timeline and pipeline timing.